Dr. Robert Zivadinov and Dr. Ralph Benedict present findings about the important role of the Thalamus in MS
Posted: March 24, 2013 Filed under: News Leave a comment »Multiple Sclerosis research: The thalamus moves into the spotlight; Atrophy of the thalamus is an important predictor of clinically definite MS, study shows
By: Ellen Goldbaum
BUFFALO, N.Y. – A growing body of research by multiple sclerosis (MS) investigators at the University at Buffalo and international partners is providing powerful new evidence that the brain’s gray matter reflects important changes in the disease that could allow clinicians to diagnose earlier and to better monitor and predict how the disease will progress.
Over the past three years, the UB researchers and their partners around the world, supported by an active fellowship program at UB’s Buffalo Neuroimaging Analysis Center (BNAC), have published journal papers and given presentations demonstrating that the thalamus region, in particular, is key to a host of issues involving MS.
“The thalamus is providing us with a new window on MS,” says Robert Zivadinov, MD, PhD, UB professor of neurology, BNAC director and leader of the research team. “In our recent studies, we have used large datasets to investigate the evolution of atrophy of the thalamus and its association with clinical impairment in MS, starting with the earliest stages of the disease. The location of the thalamus in the brain, its unique function and its vulnerability to changes wrought by the disease make the thalamus a critical barometer of the damage that MS causes to the brain.”
Zivadinov and UB professor of neurology Ralph Benedict discuss the new research in a video at (http://youtu.be/QhsaHeBjZrA).
At the annual meeting of the American Academy of Neurology today, Zivadinov will discuss a study he performed in collaboration with colleagues from Charles University in Prague. The study found that atrophy of the thalamus, determined with MRI, can help identify which patients with clinically isolated syndrome (CIS), a patient’s first episode of MS, are at risk for developing clinically definite MS. Such a tool would be immensely helpful to clinicians, Zivadinov notes.
http://www.buffalo.edu/news/releases/2013/03/028.html
Sen. Grisanti and UB researchers to advocate state funding for Multiple Sclerosis research
Posted: March 14, 2013 Filed under: News 1 Comment »Media Advisory: State Sen. Grisanti and UB researchers advocate state funding for NYS Multiple Sclerosis Registry and Consortium
WATCH THE SUPPORT:
http://buffalo.ynn.com/content/647849/ms-researchers-look-to-albany-for-support/
BUFFALO, N.Y. — New York State Senator Mark Grisanti will join multiple sclerosis researchers at the University at Buffalo and patients to advocate for funding by New York State to maintain and expand the New York State MS Registry and the New York State MS Consortium, directed by Bianca Weinstock-Guttman, MD, UB professor of neurology.
When: 1 p.m., March 15, 2013
Where: UB’s Clinical and Translational Science Center, 5 floor, above the Gates Vascular Institute, 875 Ellicott Street, Buffalo
Why: MS Awareness Week runs from March 11 to 17. The incidence of MS in Western New York is twice the national average. The disease costs New York State between $1.5 and $2.3 billion each year. Support for the registry and consortium of 15 MS centers across the state will facilitate NYS research on MS, boost physician knowledge about the disease and improve the quality of life for the 30,000 New York State residents with MS.
http://www.buffalo.edu/news/releases/2013/03/018.html
Speakers will include:
· State Sen. Mark Grisanti, a member of the MS Legislative Alliance for the New York State Senate, and whose family has been affected by MS
· Bianca Weinstock-Guttman, MD, UB professor of neurology in the School of Medicine and Biomedical Sciences, and director of the NYS MS Registry
· Murali Ramanathan, PhD, UB professor of pharmaceutical sciences in the School of Pharmacy and Pharmaceutical Sciences and MS researcher
· An MS patient
Press arrangements: Ellen Goldbaum of UB University Communications at 645-4605 and 771-9255 onsite.
ANNETTE FUNICELLO RESEARCH FUND Encourages Support for Pediatric MS Research
Posted: January 29, 2013 Filed under: News Leave a comment »The ANNETTE FUNICELLO RESEARCH FUND FOR NEUROLOGICAL DISEASES is calling Mousketeer and Beach Party fans to support multiple sclerosis research by world-renowned MS researcher, Robert Zivadinov of the University at Buffalo.
Your gift will be matched up to $7,500 by the Annette Funicello Research Fund.
Your support will allow Dr. Zivadinov and his team at the Buffalo Neuroimaging Analysis Center to learn more about Pediatric Multiple Sclerosis.
To make a gift, go to: http://www.giving.buffalo.edu/funicello
For information about MS research at University at Buffalo by Dr. Zivadinov, go to: www.BNAC.net
For information about the Annette Funicello Research Fund for Neurological Diseases, go to: https://calfund.org/page.aspx?pid=638
If you want to distribute flyers for this excellent cause: Funicello Fund Flyer
MS Study involving stem cells at UB Dept. of Neurology
Posted: January 15, 2013 Filed under: News Leave a comment »Buffalo study offers hope to multiple sclerosis patients
Scientists in recent years have found a way to infuse stem cells into the brains of animals to repair damage to the central nervous system, offering some of the most encouraging news yet for multiple sclerosis patients.
Now, a key $12.1 million study soon will be under way in Buffalo and two other upstate medical centers that will for the first time begin to test the procedure in people.
The hope is that the stem cells will generate new myelin, the fatty substance that surrounds nerves like the insulation on a wire. Myelin is damaged in MS, leading to weak or lost signals between nerves. Eventually, the painful disease spreads in a slow, unpredictable path toward paralysis.
by: Henry Davis
Read about it: www.buffalonews.com
The state of New York has committed to fund the project through the stem cell fund.
Dr. Bianca Weinstock-Guttman, MD, co-principal investigator on the study, is Professor of Neurology, State University of New York at Buffalo, and Director of the Baird MS Center at The Jacobs Neurological Institute. She is also the Director of the Pediatric MS Center of the Jacobs Neurological Institute, one of six centers of excellence established by the National MS Society. In addition, she also serves as Executive Director of the New York State Multiple Sclerosis Consortium (NYSMSC).
Business First: UB to be part of MS research effort
Posted: December 20, 2012 Filed under: News Leave a comment »The University at Buffalo School of Medicine & Biomedical Sciences will share in a $12.1 million state research grant aimed at halting the progression of disability in multiple sclerosis patients.
Read about it: http://m.bizjournals.com/buffalo/
by Tracey Drury
Dr. Bianca Weinstock-Guttman, MD, co-principal investigator on the study, is Professor of Neurology, State University of New York at Buffalo, and Director of the Baird MS Center at The Jacobs Neurological Institute. She is also the Director of the Pediatric MS Center of the Jacobs Neurological Institute, one of six centers of excellence established by the National MS Society. In addition, she also serves as Executive Director of the New York State Multiple Sclerosis Consortium (NYSMSC).
Severe morning sickness patients get relief from anti-seizure drug
Posted: December 11, 2012 Filed under: News Leave a comment »Good news may be on the horizon for Kate Middleton, Duchess of Cambridge, and other women stricken with severe nausea and vomiting during pregnancy, thanks to the work of a UB faculty member who is conducting research on a drug that is showing success treating pregnant women with this condition.
Thomas Guttuso Jr., assistant professor of neurology in the School of Medicine and Biomedical Sciences, has been studying the drug gabapentin, an anti-seizure and anti-pain drug that he previously studied in cancer patients receiving chemotherapy.
Read about it: http://www.buffalo.edu/ubreporter/
By Ellen Goldbaum
Before Canadian Senate, Zivadinov Urges Caution for CCSVI Treatment
Posted: November 25, 2012 Filed under: News Leave a comment »Before Canadian Senate, Zivadinov Urges Caution for CCSVI Treatment
Robert Zivadinov, MD, PhD, recently told the Canadian Senate that only patients in approved clinical trials should receive endovascular treatment for chronic cerobrospinal venous insufficiency.
